These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36220418)

  • 1. [Neo/adjuvant immunotherapy in the treatment of nonsmall cell lung cancer].
    Svatoň M; Blažek J; Burešová M; Vodička J
    Vnitr Lek; 2022; 68(4):217-220. PubMed ID: 36220418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer.
    Dunne EG; Fick CN; Isbell JM; Chaft JE; Altorki N; Park BJ; Spicer J; Forde PM; Gomez D; Iyengar P; Harpole DH; Stinchcombe TE; Liberman M; Bott MJ; Adusumilli PS; Huang J; Rocco G; Jones DR
    Ann Thorac Surg; 2024 Jul; 118(1):119-129. PubMed ID: 38316378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review.
    West HJ; Kim JY
    JAMA Oncol; 2024 Feb; 10(2):249-255. PubMed ID: 38153722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC): Current Evidence and Perspectives.
    Lazzari C; Spagnolo CC; Ciappina G; Di Pietro M; Squeri A; Passalacqua MI; Marchesi S; Gregorc V; Santarpia M
    Curr Oncol; 2023 Mar; 30(4):3684-3696. PubMed ID: 37185393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant immunotherapy in nonsmall cell lung cancer.
    Pall G
    Curr Opin Oncol; 2021 Jan; 33(1):59-63. PubMed ID: 33229874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease.
    Sathiyapalan A; Baloush Z; Ellis PM
    Curr Oncol; 2023 Oct; 30(11):9514-9529. PubMed ID: 37999109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in patients with early stage resectable nonsmall cell lung cancer.
    Ghysen K; Vansteenkiste J
    Curr Opin Oncol; 2019 Jan; 31(1):13-17. PubMed ID: 30325753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Checkmate 77T: Perioperative chemoimmunotherapy outperforms in early-stage NSCLC.
    Brazel D; Nagasaka M
    Med; 2024 Aug; 5(8):852-855. PubMed ID: 39127033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
    Christopoulos P
    Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated management of stage III in nonsmall cell lung cancer: where do perioperative chemotherapy and immunotherapy fit?
    Collazo-Lorduy A; Blanco M; Calvo V; Provencio M
    Curr Opin Pulm Med; 2024 Jul; 30(4):346-351. PubMed ID: 38712693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.
    Nagasaka M; Gadgeel SM
    Expert Rev Anticancer Ther; 2018 Jan; 18(1):63-70. PubMed ID: 29168933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy.
    John AO; Ramnath N
    Oncologist; 2023 Sep; 28(9):752-764. PubMed ID: 37338126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?
    Buffoni L; Vavalà T; Novello S
    Curr Treat Options Oncol; 2016 Oct; 17(10):54. PubMed ID: 27523606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma.
    van Akkooi ACJ; Blank C; Eggermont AMM
    Eur J Cancer; 2023 Mar; 182():38-42. PubMed ID: 36738540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer.
    Isaacs J; Stinchcombe TE
    Drugs; 2022 Jun; 82(8):855-863. PubMed ID: 35596880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant vs Adjuvant Chemoimmunotherapy for Stage II-IIIB Non-Small Cell Lung Cancer.
    Martins RS; Razi SS; Alnajar A; Poulikidis K; Latif MJ; Luo J; Bhora FY
    Ann Thorac Surg; 2024 Sep; 118(3):672-681. PubMed ID: 38290596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.
    Hong T; Sun T; Zhang M; Liu X; Yuan Y; Dolo PR; Chen B; Zhang H
    Thorac Cancer; 2021 Oct; 12(20):2796-2802. PubMed ID: 34463034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant or neoadjuvant chemotherapy in minimal N2 stage IIIA nonsmall cell lung cancer.
    De Craene S; Surmont V; van Meerbeeck JP
    Curr Opin Oncol; 2010 Mar; 22(2):102-11. PubMed ID: 20180283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant therapy in non-small cell lung cancer.
    Grant C; Hagopian G; Nagasaka M
    Crit Rev Oncol Hematol; 2023 Oct; 190():104080. PubMed ID: 37532102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.